BR0014269A - Compostos de lactamas, seus sais e pró-drogas farmaceuticamente aceitáveis, composição farmacêutica, método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, método de inibição da atividade da "alfa"-secretase e usos dos compostos - Google Patents
Compostos de lactamas, seus sais e pró-drogas farmaceuticamente aceitáveis, composição farmacêutica, método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, método de inibição da atividade da "alfa"-secretase e usos dos compostosInfo
- Publication number
- BR0014269A BR0014269A BR0014269-7A BR0014269A BR0014269A BR 0014269 A BR0014269 A BR 0014269A BR 0014269 A BR0014269 A BR 0014269A BR 0014269 A BR0014269 A BR 0014269A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- amyloid
- production
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTOS DE LACTAMAS, SEUS SAIS E PRó-DROGAS FARMACEUTICAMENTE ACEITáVEIS, COMPOSIçãO FARMACêUTICA, MéTODO DE TRATAMENTO DE DISFUNçõES NEUROLóGICAS ASSOCIADAS COM A PRODUçãO DE <225>-AMILóIDE, MéTODO DE INIBIçãO DA ATIVIDADE DA <sym>-SECRETASE E USOS DOS COMPOSTOS". A presente invenção refere-se a lactamas inovadoras que possuem a fórmula (I), suas composições farmacêuticas e seus métodos de utilização. Esses compostos inovadores inibem o processamento de proteína precursora de amilóide e, mais especificamente, inibem a produção de peptídeo-A<225>, de forma a agirem para evitar a formação de depósitos neurológicos de proteína de amilóide. Mais especificamente, a presente invenção refere-se ao tratamento de disfunções neurológicas relativas à produção de <255>-amilóide, tais como o mal de Alzheimer e a Síndrome de Down.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15351199P | 1999-09-13 | 1999-09-13 | |
| US22438800P | 2000-08-09 | 2000-08-09 | |
| PCT/US2000/024967 WO2001019797A2 (en) | 1999-09-13 | 2000-09-13 | HYDROXYALKANOYL AMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0014269A true BR0014269A (pt) | 2002-07-02 |
Family
ID=26850619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0014269-7A BR0014269A (pt) | 1999-09-13 | 2000-09-13 | Compostos de lactamas, seus sais e pró-drogas farmaceuticamente aceitáveis, composição farmacêutica, método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, método de inibição da atividade da "alfa"-secretase e usos dos compostos |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1212306A2 (pt) |
| JP (1) | JP2003509411A (pt) |
| CN (1) | CN1399634A (pt) |
| AU (1) | AU783914B2 (pt) |
| BR (1) | BR0014269A (pt) |
| CA (1) | CA2377221A1 (pt) |
| IL (1) | IL147774A0 (pt) |
| MX (1) | MXPA02001813A (pt) |
| WO (1) | WO2001019797A2 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960576B2 (en) | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
| US7119085B2 (en) | 2000-03-23 | 2006-10-10 | Elan Pharmaceuticals, Inc. | Methods to treat alzheimer's disease |
| MXPA02009729A (es) * | 2000-04-03 | 2003-03-27 | Bristol Myers Squibb Pharma Co | Lactamas ciclicas como inhibidores de la produccion de la proteina a-beta. |
| AU2001257006A1 (en) | 2000-04-11 | 2001-10-23 | Du Pont Pharmaceuticals Company | Substituted lactams as inhibitors of abeta protein production |
| US6878363B2 (en) | 2000-05-17 | 2005-04-12 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| GB0012671D0 (en) * | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
| EP1666452A2 (en) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| US7399775B2 (en) * | 2001-12-27 | 2008-07-15 | Daiichi Pharmaceutical Co., Ltd. | β-amyloid protein production/secretion inhibitor |
| WO2003094854A2 (en) | 2002-05-07 | 2003-11-20 | Elan Pharmaceuticals, Inc. | Succinoyl aminopyrazoles and related compounds |
| TW200502221A (en) * | 2002-10-03 | 2005-01-16 | Astrazeneca Ab | Novel lactams and uses thereof |
| JP4220548B2 (ja) | 2003-06-05 | 2009-02-04 | エラン ファーマシューティカルズ，インコーポレイテッド | アシル化されたアミノ酸・アミジルピラゾール、および関連化合物 |
| JP2010518064A (ja) | 2007-02-12 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | Ａｄおよび関連状態の治療のためのピペラジン誘導体 |
| EP2146722A4 (en) | 2007-05-10 | 2011-08-03 | Amr Technology Inc | ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND THEIR USE FOR BLOCKING THE RECOVERY OF NOREPINEPHRIN, DOPAMINE AND SEROTONINE |
| PT2222636E (pt) | 2007-12-21 | 2013-07-16 | Ligand Pharm Inc | Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações |
| EP2291181B9 (en) | 2008-04-18 | 2013-09-11 | University College Dublin National University Of Ireland, Dublin | Captodiamine for the treatment of depression symptoms |
| EP3613418A1 (en) | 2014-01-17 | 2020-02-26 | Ligand Pharmaceuticals, Inc. | Methods and compositions for modulating hormone levels |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| KR20000069075A (ko) * | 1996-11-22 | 2000-11-25 | 진 엠. 듀발 | Ｎ-(아릴/헤테로아릴/알킬아세틸)아미노산 아미드, 이들을 함유하는 제약 조성물, 및 이들 화합물을 사용하여 베타-아밀로이드 펩티드의 방출 및(또는) 합성의 억제 방법 |
| JP3812952B2 (ja) | 1996-12-23 | 2006-08-23 | エラン ファーマシューティカルズ，インコーポレイテッド | シクロアルキル、ラクタム、ラクトンおよびその関連化合物およびその医薬組成物、並びに該化合物を用いたβ−アミロイドペプチドの放出および／またはその合成を阻害する方法 |
| IL135564A0 (en) * | 1997-12-22 | 2001-05-20 | Elan Pharm Inc | POLYCYCLIC α-AMINO-ɛ-CAPROLACTAMS AND RELATED COMPOUNDS |
| WO1999066934A1 (en) | 1998-06-22 | 1999-12-29 | Elan Pharmaceuticals, Inc. | CYCLIC AMINO ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS |
| HRP990246A2 (en) | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
| WO2000038618A2 (en) | 1998-12-24 | 2000-07-06 | Du Pont Pharmaceuticals Company | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
-
2000
- 2000-09-13 EP EP00963374A patent/EP1212306A2/en not_active Withdrawn
- 2000-09-13 AU AU74797/00A patent/AU783914B2/en not_active Ceased
- 2000-09-13 IL IL14777400A patent/IL147774A0/xx unknown
- 2000-09-13 CN CN00812784A patent/CN1399634A/zh active Pending
- 2000-09-13 JP JP2001523377A patent/JP2003509411A/ja active Pending
- 2000-09-13 BR BR0014269-7A patent/BR0014269A/pt not_active Application Discontinuation
- 2000-09-13 WO PCT/US2000/024967 patent/WO2001019797A2/en active IP Right Grant
- 2000-09-13 MX MXPA02001813A patent/MXPA02001813A/es unknown
- 2000-09-13 CA CA002377221A patent/CA2377221A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1399634A (zh) | 2003-02-26 |
| WO2001019797A3 (en) | 2002-04-11 |
| EP1212306A2 (en) | 2002-06-12 |
| AU7479700A (en) | 2001-04-17 |
| CA2377221A1 (en) | 2001-03-22 |
| AU783914B2 (en) | 2005-12-22 |
| JP2003509411A (ja) | 2003-03-11 |
| IL147774A0 (en) | 2002-08-14 |
| WO2001019797A2 (en) | 2001-03-22 |
| MXPA02001813A (es) | 2004-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9917082A (pt) | Compostos inibidores da produção de proteìnas a"beta", método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase | |
| BR0106717A (pt) | Compostos, composição farmacêutica e usos dos compostos de lactama inovadora | |
| BR0014269A (pt) | Compostos de lactamas, seus sais e pró-drogas farmaceuticamente aceitáveis, composição farmacêutica, método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, método de inibição da atividade da "alfa"-secretase e usos dos compostos | |
| BR9912969A (pt) | Composto, composição farmacêutica, método para o tratamento dos distúrbios neurológicos associados com a produção de b-amilóide, método para o tratamento da doença de alzheimer associada com a produção de b-amilóide, método para o tratamento dos distúrbios neurológicos associados com a produção de b-amilóide e método para inibir a atividade de y-secretase | |
| DE69429527T2 (de) | Inhibitoren von beta-amyloid-protein-herstellung | |
| BR0110051A (pt) | Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer | |
| BRPI0011867B8 (pt) | preparação farmacêutica de levodopa/carbidopa/entacapona e processo para preparação da mesma | |
| BR0116201A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica que compreende o composto, utilização do composto, processo para o tratamento e profilaxia de distúrbios e para o tratamento de obesidade | |
| BR9709959A (pt) | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas | |
| BR0108610A (pt) | Compostos azapolicìclicos condensados com arila | |
| ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| BR9807876A (pt) | Compostos heterocìclicos e seu uso para inibição de peptìdeo beta-amilóide | |
| BR0012590A (pt) | Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central | |
| BR9814592A (pt) | "compostos azopolicìclicos condensados com arila" | |
| BR9913319A (pt) | Composições e métodos para tratamento de doenças mitocondriais | |
| CY1110391T1 (el) | Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους | |
| MX9307062A (es) | Derivado de quinuclidina para el tratamiento de los trastornos inflamatorios y del sistema nervioso central. | |
| DE69731610D1 (de) | Orale verabreichung wirksamer mengen von hyaluronsäure | |
| CA2501799A1 (en) | Pyrazole compounds for treatment of neurodegenerative disorders | |
| BR0008958A (pt) | Inibidores de reabsorção de monoamina para otratamento de distúrbios do snc | |
| DE69912808D1 (de) | Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel | |
| BR9812577A (pt) | Composto, processo para preparar o mesmo, composição farmacêutica, e, processo para tratar infecções bacterianas | |
| BR0312780A (pt) | Compostos de tiofeno-carboxamida substituìda para o tratamento de inflamação | |
| BRPI0409151A (pt) | uso de derivados de 10-hidróxi-10,11-diidrocarbamazepina para o tratamento de transtornos afetivos | |
| DE60108130D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |